JP2008521870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521870A5 JP2008521870A5 JP2007543910A JP2007543910A JP2008521870A5 JP 2008521870 A5 JP2008521870 A5 JP 2008521870A5 JP 2007543910 A JP2007543910 A JP 2007543910A JP 2007543910 A JP2007543910 A JP 2007543910A JP 2008521870 A5 JP2008521870 A5 JP 2008521870A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dom4
- sequence
- dom7r
- dom7h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010932 Interleukin-1 receptor type 1 Human genes 0.000 claims 31
- 108050001109 Interleukin-1 receptor type 1 Proteins 0.000 claims 31
- 101100268517 Mus musculus Serpina1d gene Proteins 0.000 claims 30
- 108060003951 Immunoglobulin Proteins 0.000 claims 23
- 102000018358 immunoglobulin Human genes 0.000 claims 23
- 239000005557 antagonist Substances 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 12
- 208000023504 respiratory system disease Diseases 0.000 claims 12
- 102000000589 Interleukin-1 Human genes 0.000 claims 11
- 108010002352 Interleukin-1 Proteins 0.000 claims 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 10
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 9
- 208000014085 Chronic respiratory disease Diseases 0.000 claims 8
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 8
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 7
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 7
- 210000004602 germ cell Anatomy 0.000 claims 7
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 6
- 238000012377 drug delivery Methods 0.000 claims 6
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims 4
- 102000007562 Serum Albumin Human genes 0.000 claims 4
- 108010071390 Serum Albumin Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 125000003827 glycol group Chemical group 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000007910 systemic administration Methods 0.000 claims 3
- 102000006395 Globulins Human genes 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 210000004969 inflammatory cell Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 210000004879 pulmonary tissue Anatomy 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 230000037317 transdermal delivery Effects 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000046824 human IL1RN Human genes 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- 229940096397 interleukin-8 Drugs 0.000 claims 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 230000036961 partial effect Effects 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000013389 whole blood assay Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63236104P | 2004-12-02 | 2004-12-02 | |
| PCT/GB2005/002163 WO2005118642A2 (en) | 2004-06-01 | 2005-05-31 | Bispecific fusion antibodies with enhanced serum half-life |
| GBGB0521621.3A GB0521621D0 (en) | 2005-10-24 | 2005-10-24 | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| PCT/GB2005/004601 WO2006059108A2 (en) | 2004-12-02 | 2005-12-01 | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008521870A JP2008521870A (ja) | 2008-06-26 |
| JP2008521870A5 true JP2008521870A5 (cg-RX-API-DMAC7.html) | 2009-01-22 |
Family
ID=38792215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543910A Pending JP2008521870A (ja) | 2004-12-02 | 2005-12-01 | 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090191217A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1863847A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008521870A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070086896A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101133084A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2005311101B8 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0518622A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2588892A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL183458A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA29669B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007006593A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20073337L (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006059108A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| CA2505326A1 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| AU2003286003B2 (en) * | 2002-11-08 | 2011-05-26 | Ablynx N.V. | Stabilized single domain antibodies |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| TW200730539A (en) * | 2005-12-01 | 2007-08-16 | Domantis Ltd | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
| AU2006321367B2 (en) * | 2005-12-01 | 2011-11-03 | Domantis Limited | Competitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
| HUE048024T2 (hu) * | 2006-08-10 | 2020-05-28 | Roy C Levitt | Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra |
| AU2013270447B2 (en) * | 2006-08-10 | 2016-10-13 | Onspira Therapeutics, Inc. | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
| GB0621513D0 (en) * | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| CA2688434A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| WO2009033661A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| KR20100061485A (ko) * | 2007-09-11 | 2010-06-07 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 피브로넥틴 단편 （１９６－２０３）의 용도 |
| TW200938222A (en) * | 2007-12-13 | 2009-09-16 | Glaxo Group Ltd | Compositions for pulmonary delivery |
| WO2009108890A1 (en) | 2008-02-27 | 2009-09-03 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| JP2011516603A (ja) | 2008-04-17 | 2011-05-26 | アブリンクス エン．ヴェー． | 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド |
| KR20110071139A (ko) * | 2008-10-21 | 2011-06-28 | 도만티스 리미티드 | Ｄｃｓｉｇｎ에 대한 결합 특이성을 갖는 리간드 |
| MX2011004558A (es) | 2008-10-29 | 2011-06-01 | Wyeth Llc | Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio. |
| KR101593285B1 (ko) | 2008-10-29 | 2016-02-11 | 아블린쓰 엔.브이. | 단일 도메인 항원 결합 분자의 제형 |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| US8758287B2 (en) | 2008-11-12 | 2014-06-24 | Marv Enterprises, LLC | Utilization of stents for the treatment of blood borne carcinomas |
| US20110311515A1 (en) * | 2009-01-14 | 2011-12-22 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| WO2010107789A1 (en) * | 2009-03-17 | 2010-09-23 | Marv Enterprises Llc | Sequential extracorporeal treatment of bodily fluids |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| PL2438087T3 (pl) * | 2009-06-05 | 2017-10-31 | Ablynx Nv | Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych |
| CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| WO2011095545A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| KR20130086141A (ko) * | 2010-04-16 | 2013-07-31 | 메디뮨 리미티드 | Ｃｏｐｄ 악화를 치료하기 위한 조성물 및 방법 |
| US8883134B2 (en) | 2010-10-20 | 2014-11-11 | Handok Pharmaceuticals, Inc. | Human interleukin-1 receptor antagonist—hybrid Fc fusion protein |
| WO2012053828A2 (ko) * | 2010-10-20 | 2012-04-26 | 주식회사 한독약품 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| US20130266567A1 (en) * | 2010-12-01 | 2013-10-10 | Haren Arulanantham | Anti-serum albumin binding single variable domains |
| CN103370075A (zh) * | 2011-02-15 | 2013-10-23 | 诺沃—诺迪斯克有限公司 | 长效il-1受体拮抗剂 |
| IL250396B (en) | 2011-06-23 | 2022-06-01 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP4350345A3 (en) | 2011-06-23 | 2024-07-24 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| EP2944654A1 (en) | 2011-06-23 | 2015-11-18 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| WO2013148405A2 (en) * | 2012-03-27 | 2013-10-03 | Felder Mitchell S | Treatment for atherosclerosis |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| WO2015081253A1 (en) | 2013-11-26 | 2015-06-04 | Biomet Biologics, Llc | Methods of mediating macrophage phenotypes |
| US11009511B2 (en) | 2014-05-16 | 2021-05-18 | Ablynx N.V. | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
| DK3143042T3 (da) | 2014-05-16 | 2020-08-31 | Ablynx Nv | Forbedrede variable immunoglobulindomæner |
| PT3204095T (pt) | 2014-10-10 | 2019-07-11 | Ablynx Nv | Dispositivo de inalação para usar na terapia com aerossóis de doenças respiratórias |
| CA2963037A1 (en) | 2014-10-10 | 2016-04-14 | Ablynx N.V. | Treatment of rsv infection |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| US11426468B2 (en) | 2014-12-19 | 2022-08-30 | Ablynx N.V. | Cysteine linked nanobody dimers |
| US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
| NO2768984T3 (cg-RX-API-DMAC7.html) | 2015-11-12 | 2018-06-09 | ||
| PL3374392T3 (pl) | 2015-11-13 | 2022-03-28 | Ablynx Nv | Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy |
| JP7046804B2 (ja) | 2015-11-18 | 2022-04-04 | アブリンクス エン．ヴェー． | 改良された血清アルブミン結合剤 |
| CA3004900C (en) | 2015-11-18 | 2021-08-10 | Merck Sharp & Dohme Corp. | Ctla4 binders |
| US20190127447A1 (en) | 2016-05-02 | 2019-05-02 | Ablynx N.V. | Treatment of rsv infection |
| KR102374912B1 (ko) | 2016-06-23 | 2022-03-16 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인에 대한 개선된 약동학적 어세이 |
| WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
| IL310340A (en) | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| US11414481B2 (en) | 2017-01-17 | 2022-08-16 | Ablynx N.V. | Serum albumin binders |
| LT3571224T (lt) | 2017-01-17 | 2024-11-11 | Ablynx Nv | Patobulintos serumo albumino rišamosios medžiagos |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| SG11201908154RA (en) | 2017-03-31 | 2019-10-30 | Ablynx Nv | Improved immunogenicity assays |
| JP7428661B2 (ja) * | 2018-05-30 | 2024-02-06 | 中外製薬株式会社 | Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド |
| JP2023523600A (ja) | 2020-04-22 | 2023-06-06 | マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド | ヒトプログラム細胞死リガンド１（ｐｄ－ｌ１）を標的とする単一可変ドメイン抗体およびその誘導体 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| US5319071A (en) * | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
| US4968607A (en) * | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5081228A (en) * | 1988-02-25 | 1992-01-14 | Immunex Corporation | Interleukin-1 receptors |
| US5296592A (en) * | 1987-11-25 | 1994-03-22 | Immunex Corporation | Process for purifying interleukin-1 receptors |
| US6511665B1 (en) * | 1987-11-25 | 2003-01-28 | Immunex Corporation | Antibodies to interleukin-1 receptors |
| US20040101528A1 (en) * | 1988-02-25 | 2004-05-27 | Dower Steven K. | Type I IL-1 receptors |
| SE509359C2 (sv) * | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
| AU2884592A (en) * | 1991-10-31 | 1993-06-07 | Victoria University Of Manchester, The | Treatment of neurological conditions by an interleukin-1 inhibiting compound |
| DE69738948D1 (de) * | 1996-12-06 | 2008-10-09 | Amgen Inc | Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten |
| US6054559A (en) * | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
| US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6326472B1 (en) * | 1997-10-15 | 2001-12-04 | Schering Corporation | Human receptor proteins; related reagents and methods |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US7115557B2 (en) * | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
| US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
| US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| EP1240337B1 (en) * | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| WO2001089549A2 (en) * | 2000-05-22 | 2001-11-29 | Hyseq, Inc. | Therapeutic uses of il-1 receptor antagonist |
| CN1294148C (zh) * | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| WO2003039466A2 (en) * | 2001-11-06 | 2003-05-15 | Applied Research Systems Ars Holding N.V. | Method of treating estrogen responsive breast cancer |
| SE0200667D0 (sv) * | 2002-03-05 | 2002-03-05 | A & Science Invest Ab | Novel use of cytokine inhibitors |
| EP2135879A3 (en) * | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| US20040038874A1 (en) * | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
| JP4317817B2 (ja) * | 2002-09-06 | 2009-08-19 | アムジェン インコーポレイテッド | 治療用ヒト抗ｉｌ−１ｒ１モノクローナル抗体 |
| AU2003286003B2 (en) * | 2002-11-08 | 2011-05-26 | Ablynx N.V. | Stabilized single domain antibodies |
| CA2505326A1 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| WO2004067778A2 (en) * | 2003-01-28 | 2004-08-12 | University Of South Florida | Differentially expressed genes in large granular lymphocyte leukemia |
| US20040224893A1 (en) * | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
-
2005
- 2005-12-01 US US11/791,781 patent/US20090191217A1/en not_active Abandoned
- 2005-12-01 BR BRPI0518622-6A patent/BRPI0518622A2/pt not_active Application Discontinuation
- 2005-12-01 JP JP2007543910A patent/JP2008521870A/ja active Pending
- 2005-12-01 KR KR1020077015202A patent/KR20070086896A/ko not_active Ceased
- 2005-12-01 CN CNA2005800476534A patent/CN101133084A/zh active Pending
- 2005-12-01 EP EP05818379A patent/EP1863847A2/en not_active Ceased
- 2005-12-01 CA CA002588892A patent/CA2588892A1/en not_active Abandoned
- 2005-12-01 MX MX2007006593A patent/MX2007006593A/es unknown
- 2005-12-01 WO PCT/GB2005/004601 patent/WO2006059108A2/en not_active Ceased
- 2005-12-01 AU AU2005311101A patent/AU2005311101B8/en not_active Ceased
-
2007
- 2007-05-28 IL IL183458A patent/IL183458A0/en unknown
- 2007-06-28 NO NO20073337A patent/NO20073337L/no not_active Application Discontinuation
- 2007-06-29 MA MA30043A patent/MA29669B1/fr unknown
-
2011
- 2011-02-09 AU AU2011200544A patent/AU2011200544A1/en not_active Abandoned